Additional activating or augmenting mutations identified in MPL transmembrane domain by deep mutational scanning screens have also been previously identified in MPN patients demonstrating an inherent susceptibility in the MPL gene [41]. This evidence concerns the gene MPL and myeloproliferative disorder.